WALGREENS BOOTS ALLIANCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.7 USD | +0.57% |
|
-2.96% | -32.21% |
| Apr. 26 | CVS Omnicare staff in Las Vegas vote to join new union | RE |
| Apr. 26 | Morgan Stanley Adjusts Price Target on Walgreens Boots Alliance to $16 From $20 | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company shows low valuation levels, with an enterprise value at 0.15 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -32.21% | 15.27B | B- | ||
| -31.97% | 10.84B | B | ||
| +8.14% | 6.04B | C | ||
| -11.41% | 5.86B | C+ | ||
| -30.42% | 6.06B | B | ||
| -0.88% | 4.71B | D- | ||
| +52.19% | 4.29B | - | C | |
| -12.31% | 3.61B | B | ||
| -14.86% | 3.33B | C- | ||
| -6.93% | 3.01B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.
